24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

144s Developmental Therapeutics—<strong>Clinical</strong> Pharmacology and Immunotherapy<br />

2508 Oral Abstract Session, Mon, 3:00 PM-6:00 PM<br />

From bench to bedside: The use <strong>of</strong> the li-Key technology to improve helper<br />

peptides for clinical use in cancer vaccines. Presenting Author: Timothy J.<br />

Vreeland, San Antonio Military Medical Center, Ft. Sam Houston, TX<br />

Background: Work involving peptide vaccines has shown that peptides<br />

containing MHC Class II epitopes, which elicit CD4� T cell responses, may<br />

play a role in potentiating an immune response. The Ii-Key peptide (amino<br />

acids 77-80 <strong>of</strong> the immune-regulatory Ii protein), when covalently linked to<br />

an MHC Class II epitope, can induce conformational change in the epitope<br />

binding groove, increasing CD4� T cell stimulation up to 250 fold. Here we<br />

present an update <strong>of</strong> results from clinical trials evaluating this novel<br />

technology in an adjuvant breast cancer vaccine targeting HER2/neu.<br />

Methods: We reviewed our trials investigating AE37, a hybrid peptide<br />

created by the addition <strong>of</strong> the Ii-Key peptide (LRMK) to AE36 (GVGSPYVS-<br />

RLLGICL), an MHC Class II-binding peptide from the intracellular domain<br />

<strong>of</strong> the HER2 protein. We have completed a phase I study and are currently<br />

conducting a randomized phase II trial <strong>of</strong> the AE37 peptide � GM-CSF in<br />

the adjuvant treatment <strong>of</strong> disease-free breast cancer patients with any level<br />

<strong>of</strong> HER2 expression (IHC 1-3� or FISH�1.2). Results: Phase I data showed<br />

the vaccine to be safe and effective in raising anti-HER2 immunity.<br />

Importantly, even the cohort <strong>of</strong> patients given AE37 without GM-CSF<br />

showed significant increases in both in vivo and in vitro immune responses.<br />

To date, we have enrolled 201 patients to our phase II trial (Vaccine<br />

(VG)�103, Control (CG)�98). Toxicity has been minimal (99% <strong>of</strong> local<br />

and systemic toxicities grade �2). VG patients have shown significant<br />

increases in both in vivo and in vitro responses to both AE36 and AE37,<br />

with consistently stronger responses to the AE37 hybrid peptide than the<br />

native AE36. With a median f/u <strong>of</strong> 22 months, Kaplan Meier projections<br />

estimate recurrence rates <strong>of</strong> 10.3% in the VG compared to 18% in the CG;<br />

a 43% risk reduction. Conclusions: The AE37 peptide vaccine appears to be<br />

effective in eliciting a strong immune response and possibly preventing<br />

breast cancer recurrence. These results provide an important pro<strong>of</strong> <strong>of</strong><br />

concept and suggest that additional studies evaluating Ii-Key hybrid<br />

peptide vaccines are warranted, whether in the field <strong>of</strong> immunotherapy or<br />

more traditional vaccines.<br />

2510 <strong>Clinical</strong> Science Symposium, Sat, 1:15 PM-2:45 PM<br />

PD-1/PD-L1 pathway as a target for cancer immunotherapy: Safety and<br />

clinical activity <strong>of</strong> BMS-936559, an anti-PD-L1 antibody, in patients with<br />

solid tumors. Presenting Author: Scott S. Tykodi, Fred Hutchinson Cancer<br />

Research Center, Seattle, WA<br />

Background: Blocking the interaction between programmed death-1 (PD-<br />

1), a co-inhibitory receptor expressed by activated T cells, and its ligand<br />

PD-L1 may enhance T-cell function. Here we describe the safety and<br />

activity from the first clinical study <strong>of</strong> BMS-936559 in patients (pts) with<br />

advanced solid tumors, further validating the importance <strong>of</strong> the PD-1/<br />

PD-L1 pathway as a target for cancer therapy. Methods: BMS-936559 was<br />

given Q2 wk IV in a 6-wk cycle at doses <strong>of</strong> 0.3�10.0 mg/kg during dose<br />

escalation and/or cohort expansion; pts could receive up to 16 cycles (48<br />

doses). Results: As <strong>of</strong> August 1, 2011, 162 pts with melanoma (MEL,<br />

n�53), non-small-cell lung (NSCLC, n�50), colorectal (n�18), renal cell<br />

(RCC, n�17), ovarian (n�17), and pancreatic (n�7) cancer were treated.<br />

Median therapy duration was 11 wks (max 99 wks). Common related<br />

adverse events (rAEs; �5% pts) included fatigue, diarrhea, infusion<br />

reaction, arthralgia, rash, and pruritus. The incidence <strong>of</strong> grade 3-4 rAEs<br />

was 8.6%. AEs <strong>of</strong> special interest included hypothyroidism, hepatitis,<br />

sarcoidosis, endophthalmitis, and myasthenia gravis; there were no drugrelated<br />

deaths. <strong>Clinical</strong> activity was observed in MEL, RCC, and NSCLC.<br />

Objective responses (ORs; RECIST 1.0) were observed in heavily pretreated<br />

pts. ORs were durable; among 16 pts with ORs, 7 had responses lasting �1<br />

yr. Two other pts had ongoing ORs with durations <strong>of</strong> 2.3 and 8.5 mo at data<br />

lock. Several pts had prolonged stable disease. Some pts had a persistent<br />

reduction in overall tumor burden in the presence <strong>of</strong> new lesions but were<br />

not categorized as responders. In NSCLC, ORs were observed irrespective<br />

<strong>of</strong> histology. Conclusions: BMS-936559 was active and generally well<br />

tolerated in pts with NSCLC, RCC, and MEL. In conjunction with data from<br />

anti-PD-1/BMS-936558 trials, this study concurrently validates the importance<br />

<strong>of</strong> the PD-1/PD-L1 pathway for cancer immunotherapy and supports<br />

further clinical development <strong>of</strong> anti-PD-1/PD-L1 directed therapy.<br />

Dose<br />

(mg/kg)<br />

MEL RCC NSCLC<br />

N a OR uPR b RR c (%) N a OR uPR b RR c (%) N a OR uPR b RR c (%)<br />

1 18 1 1 11 0 - - - 11 0 0 0<br />

3 17 5 1 35 0 - - - 13 1 0 8<br />

10 17 3 0 18 17 2 1 18 25 4 3 28<br />

a response evaluable pts<br />

b unconfirmed PR<br />

c response rate ([OR � uPR] � N)<br />

CRA2509 <strong>Clinical</strong> Science Symposium, Sat, 1:15 PM-2:45 PM<br />

Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors:<br />

<strong>Clinical</strong> activity, safety, and a potential biomarker for response.<br />

Presenting Author: Suzanne Louise Topalian, The Johns Hopkins University<br />

School <strong>of</strong> Medicine, Baltimore, MD<br />

The full, final text <strong>of</strong> this abstract will be available at<br />

abstract.asco.org at 12:01 AM (EDT) on Saturday, June 2,<br />

2012, and in the <strong>Annual</strong> <strong>Meeting</strong> <strong>Proceedings</strong> online<br />

supplement to the June 20, 2012, issue <strong>of</strong> Journal <strong>of</strong><br />

<strong>Clinical</strong> Oncology. Onsite at the <strong>Meeting</strong>, this abstract will<br />

be printed in the Saturday edition <strong>of</strong> ASCO Daily News.<br />

2511 <strong>Clinical</strong> Science Symposium, Sat, 1:15 PM-2:45 PM<br />

Costimulatory effect <strong>of</strong> agonistic 4-1BB antibody on proliferation and<br />

effector phenotype <strong>of</strong> tumor-infiltrating lymphocytes in melanoma. Presenting<br />

Author: Amod Sarnaik, H. Lee M<strong>of</strong>fitt Cancer Canter & Research<br />

Institute, Tampa, FL<br />

Background: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL)<br />

is a promising form <strong>of</strong> immunotherapy with a 20-30% durable response<br />

rate. Its widespread implementation is limited by the relatively long time<br />

needed to establish TIL in vitro and the lack <strong>of</strong> effective tumor reactivity.<br />

Our objective was to incorporate co-stimulation with 4-1BB agonism to<br />

optimize TIL growth preparation time and tumor reactivity to improve<br />

outcomes. Methods: 7 metastatic melanoma patients were consented to an<br />

IRB-approved tissue procurement protocol. For each specimen, TIL were<br />

propagated in vitro from 4 melanoma tumor fragments per condition with<br />

standard 6000 IU/mL <strong>of</strong> IL-2 and either 10 ug/mL <strong>of</strong> 4-1BB agonistic<br />

antibody (BMS-663513) or its isotype control. After 3 weeks, TIL were<br />

counted and phenotyped using flow cytometry. TIL were re-stimulated with<br />

HLA-matched melanomas and assessed for interferon-� (IFN�) release by<br />

ELISA. Statistical comparisons involved the 2-tailed, paired t test using<br />

GraphPad Prism s<strong>of</strong>tware. Results: 4-1BB treatment yielded a median<br />

4.3x10 7 TIL (range 1.1x10 7 -8.4x10 7 ) compared to a median 2.3x10 7<br />

cells in the control (range 1.5x10 6 -5.3x10 7 ,p� 0.009). This is clinically<br />

significant as the initial minimum target number for TIL generation is<br />

3x10 7 . On phenotypic analysis compared to control, 4-1BB treatment<br />

resulted in a 1.5X higher CD8 � cell numbers (p�0.02), a 6X lower CD4 �<br />

cell numbers (p�0.02), and 5.5X lower CD4 � CD25 � FoxP3 � Treg cell<br />

numbers (p�0.09). A paired sample was re-stimulated in triplicate with<br />

HLA-matched tumor target, and ELISA <strong>of</strong> the supernatant treated with<br />

4-1BB yielded 1.6 fold higher IFN� (p�0.05). A paired sample was then<br />

assayed for known markers <strong>of</strong> T cell cytolytic activity: EOMES and perforin.<br />

4-1BB treatment resulted in 34.5% EOMES and perforin double positive<br />

TIL compared to 18.8% in the control group. Conclusions: 4-1BB agonism<br />

is associated with enhanced kinetics <strong>of</strong> TIL proliferation, increased yield <strong>of</strong><br />

CD8 � TIL, lower Treg numbers, increased markers <strong>of</strong> cytolysis, and<br />

enhanced IFN� release upon tumor re-stimulation. 4-1BB agonism may be<br />

a useful adjuvant in the generation <strong>of</strong> TIL in future clinical trials.<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!